Go Pro
→ Iran War WARNING: Something Just Changed (From Banyan Hill Publishing) (Ad)tc pixel Free UPC Stock Alerts

Universe Pharmaceuticals (UPC) Competitors

Universe Pharmaceuticals logo
$4.86 +0.11 (+2.32%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$4.58 -0.29 (-5.86%)
As of 09/18/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

UPC vs. MNOV, DWTX, ZYBT, CING, and TENX

Should you buy Universe Pharmaceuticals stock or one of its competitors? Universe Pharmaceuticals's main competitors and comparable companies include MediciNova (MNOV), Dogwood Therapeutics (DWTX), Zhengye Biotechnology (ZYBT), Cingulate (CING), and Tenax Therapeutics (TENX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Universe Pharmaceuticals compare to MediciNova?

MediciNova (NASDAQ:MNOV) and Universe Pharmaceuticals (NASDAQ:UPC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

In the previous week, MediciNova had 7 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 7 mentions for MediciNova and 0 mentions for Universe Pharmaceuticals. MediciNova's average media sentiment score of 0.66 beat Universe Pharmaceuticals' score of 0.00 indicating that MediciNova is being referred to more favorably in the media.

Company Overall Sentiment
MediciNova Positive
Universe Pharmaceuticals Neutral

MediciNova has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market. Comparatively, Universe Pharmaceuticals has a beta of 1.58, meaning that its stock price is 58% more volatile than the broader market.

MediciNova presently has a consensus target price of $7.75, suggesting a potential upside of 133.43%. Given MediciNova's stronger consensus rating and higher probable upside, equities analysts plainly believe MediciNova is more favorable than Universe Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MediciNova
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
2 Strong Buy rating(s)
2.86
Universe Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Universe Pharmaceuticals has higher revenue and earnings than MediciNova.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MediciNova$410K398.56-$12M-$0.21N/A
Universe Pharmaceuticals$17.86M1.37-$3.67MN/AN/A

9.9% of MediciNova shares are held by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are held by institutional investors. 14.0% of MediciNova shares are held by company insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Universe Pharmaceuticals has a net margin of 0.00% compared to MediciNova's net margin of -1,168.70%. Universe Pharmaceuticals' return on equity of 0.00% beat MediciNova's return on equity.

Company Net Margins Return on Equity Return on Assets
MediciNova-1,168.70% -26.51% -24.39%
Universe Pharmaceuticals N/A N/A N/A

Summary

MediciNova beats Universe Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to Dogwood Therapeutics?

Universe Pharmaceuticals (NASDAQ:UPC) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

Universe Pharmaceuticals has higher revenue and earnings than Dogwood Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Universe Pharmaceuticals$17.86M1.37-$3.67MN/AN/A
Dogwood TherapeuticsN/AN/A-$34.26M-$8.95N/A

Dogwood Therapeutics has a consensus target price of $12.00, indicating a potential upside of 610.06%. Given Dogwood Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Dogwood Therapeutics is more favorable than Universe Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Universe Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Dogwood Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

0.2% of Universe Pharmaceuticals shares are held by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are held by institutional investors. 57.4% of Universe Pharmaceuticals shares are held by insiders. Comparatively, 0.3% of Dogwood Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Universe Pharmaceuticals has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market.

Universe Pharmaceuticals' return on equity of 0.00% beat Dogwood Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Universe PharmaceuticalsN/A N/A N/A
Dogwood Therapeutics N/A -75.55%-40.28%

In the previous week, Dogwood Therapeutics had 4 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 4 mentions for Dogwood Therapeutics and 0 mentions for Universe Pharmaceuticals. Dogwood Therapeutics' average media sentiment score of 0.25 beat Universe Pharmaceuticals' score of 0.00 indicating that Dogwood Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Universe Pharmaceuticals Neutral
Dogwood Therapeutics Neutral

Summary

Dogwood Therapeutics beats Universe Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to Zhengye Biotechnology?

Zhengye Biotechnology (NASDAQ:ZYBT) and Universe Pharmaceuticals (NASDAQ:UPC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

In the previous week, Zhengye Biotechnology's average media sentiment score of 0.00 equaled Universe Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Zhengye Biotechnology Neutral
Universe Pharmaceuticals Neutral

Zhengye Biotechnology has a beta of -2.56, indicating that its stock price is 356% less volatile than the broader market. Comparatively, Universe Pharmaceuticals has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zhengye Biotechnology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Universe Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

0.2% of Universe Pharmaceuticals shares are owned by institutional investors. 57.4% of Universe Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Universe Pharmaceuticals has higher revenue and earnings than Zhengye Biotechnology.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zhengye Biotechnology$16.64M3.90-$9.98MN/AN/A
Universe Pharmaceuticals$17.86M1.37-$3.67MN/AN/A

Company Net Margins Return on Equity Return on Assets
Zhengye BiotechnologyN/A N/A N/A
Universe Pharmaceuticals N/A N/A N/A

Summary

Universe Pharmaceuticals beats Zhengye Biotechnology on 5 of the 6 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to Cingulate?

Cingulate (NASDAQ:CING) and Universe Pharmaceuticals (NASDAQ:UPC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

Universe Pharmaceuticals' return on equity of 0.00% beat Cingulate's return on equity.

Company Net Margins Return on Equity Return on Assets
CingulateN/A -238.40% -128.67%
Universe Pharmaceuticals N/A N/A N/A

In the previous week, Cingulate had 1 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 1 mentions for Cingulate and 0 mentions for Universe Pharmaceuticals. Cingulate's average media sentiment score of 0.00 equaled Universe Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Cingulate Neutral
Universe Pharmaceuticals Neutral

Universe Pharmaceuticals has higher revenue and earnings than Cingulate.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CingulateN/AN/A-$22.45M-$3.59N/A
Universe Pharmaceuticals$17.86M1.37-$3.67MN/AN/A

Cingulate currently has a consensus price target of $27.00, indicating a potential upside of 415.27%. Given Cingulate's stronger consensus rating and higher probable upside, analysts plainly believe Cingulate is more favorable than Universe Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cingulate
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Universe Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Cingulate has a beta of -0.88, suggesting that its share price is 188% less volatile than the broader market. Comparatively, Universe Pharmaceuticals has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market.

41.3% of Cingulate shares are held by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are held by institutional investors. 5.3% of Cingulate shares are held by insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Universe Pharmaceuticals beats Cingulate on 6 of the 11 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to Tenax Therapeutics?

Tenax Therapeutics (NASDAQ:TENX) and Universe Pharmaceuticals (NASDAQ:UPC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

1.7% of Tenax Therapeutics shares are owned by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are owned by institutional investors. 10.8% of Tenax Therapeutics shares are owned by company insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Universe Pharmaceuticals' return on equity of 0.00% beat Tenax Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tenax TherapeuticsN/A -61.54% -57.42%
Universe Pharmaceuticals N/A N/A N/A

In the previous week, Tenax Therapeutics had 9 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 9 mentions for Tenax Therapeutics and 0 mentions for Universe Pharmaceuticals. Tenax Therapeutics' average media sentiment score of 1.51 beat Universe Pharmaceuticals' score of 0.00 indicating that Tenax Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Tenax Therapeutics Very Positive
Universe Pharmaceuticals Neutral

Universe Pharmaceuticals has higher revenue and earnings than Tenax Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tenax TherapeuticsN/AN/A-$52.60M-$1.48N/A
Universe Pharmaceuticals$17.86M1.37-$3.67MN/AN/A

Tenax Therapeutics currently has a consensus price target of $14.00, indicating a potential upside of 636.84%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tenax Therapeutics is more favorable than Universe Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tenax Therapeutics
1 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.40
Universe Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Tenax Therapeutics has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, Universe Pharmaceuticals has a beta of 1.58, meaning that its stock price is 58% more volatile than the broader market.

Summary

Tenax Therapeutics beats Universe Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Get Universe Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for UPC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UPC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

UPC vs. The Competition

Export
MetricUniverse PharmaceuticalsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$24.42M$12.47B$7.24B$13.19B
Dividend YieldN/A2.64%2.57%12.81%
P/E RatioN/A797.25275.4925.40
Price / Sales1.37753.62646.0189.45
Price / CashN/A86.3676.2551.42
Price / Book0.0510.5310.466.33
Net Income-$3.67M$2.82B$3.49B$358.33M
7 Day Performance11.47%1.69%0.59%1.12%
1 Month Performance-8.82%0.24%-1.74%-2.39%
1 Year Performance8.24%3.95%18.13%5.35%

Universe Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
UPC
Universe Pharmaceuticals
0.6263 of 5 stars		$4.86
+2.3%		N/A+8.2%$24.42M$17.86MN/A216
MNOV
MediciNova
2.4719 of 5 stars		$1.63
flat		$8.33
+411.2%		+161.4%$80.23M$410KN/A10
DWTX
Dogwood Therapeutics
2.5294 of 5 stars		$2.29
flat		$12.00
+424.0%		-66.3%$77.84MN/AN/A5
ZYBT
Zhengye Biotechnology
N/A$1.61
flat		N/A-85.2%$76.30M$16.64MN/A278
CING
Cingulate
2.1534 of 5 stars		$5.10
flat		$27.00
+429.4%		+48.0%$74.16MN/AN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:UPC) was last updated on 9/20/2026 by MarketBeat.com Staff.
From Our Partners
“Elon’s nightmare” could fund your retirement
Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...
Chaikin Analytics | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
NVDA CEO says it’s a "once-in-a-generation opportunity"
NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...
Monument Traders Alliance | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...
TradeSmith | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
Iran War: Why Is Trump Protecting THEM?
A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military prote...
Banyan Hill Publishing | Sponsoredtc pixel
Analyst nicknamed “The Prophet” issues new warning for America
Whitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...
Stansberry Research | Sponsoredtc pixel